The effect of hormonal manipulation on urinary function following permanent prostate brachytherapy

Brachytherapy

Volumn 3, Issue 1, 2004, Pages 22-29

  Merrick, Gregory S ^a,b   Butler, Wayne M ^a,b   Wallner, Kent E ^c   Murray, Brian ^a   Allen, Zachariah ^a   Lief, Jonathan H ^a,b   Galbreath, Robert W ^a,b  

^a WHEELING HOSPITAL   (United States)

^b WHEELING JESUIT UNIVERSITY   (United States)

^c Puget Sound Health Care System   (United States)

Author keywords

Brachytherapy; Prostate; TURP; Urinary morbidity; Urinary retention

Indexed keywords

HORMONE; IODINE 125; PALLADIUM 103;

AGE; ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER SIZE; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG SENSITIVITY; EXTERNAL BEAM RADIOTHERAPY; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MICTURITION; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION; RADIATION DOSE; REGRESSION ANALYSIS; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; ULTRASOUND; URETHRA; URINE CATHETER;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BRACHYTHERAPY; COHORT STUDIES; COMBINED MODALITY THERAPY; HUMANS; IODINE RADIOISOTOPES; MALE; PALLADIUM; PROSTATIC NEOPLASMS; RADIOISOTOPES; RETROSPECTIVE STUDIES; TRANSURETHRAL RESECTION OF PROSTATE; URINARY CATHETERIZATION; URINARY RETENTION;

EID: 1942446367     PISSN: 15384721     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brachy.2003.12.001     Document Type: Article

References (24)

1. Merrick G.S., Wallner K.E., Butler W.M. Permanent interstitial brachytherapy in the management of carcinoma of the prostate gland. J Urol. 169:2003;1643-1652.
2. Merrick G.S., Wallner K.E., Butler W.M. Minimizing prostate brachytherapy-related morbidity. Urology. 62:2003;786-792.
3. Merrick G.S., Butler W.M., Lief J.H., et al. Temporal resolution of urinary morbidity following prostate brachytherapy. Int J Radiat Oncol Biol Phys. 47:2000;121-128.
4. Han B.H., Demel K.C., Wallner K., et al. Patient reported complications after prostate brachytherapy. J Urol. 166:2001;953-957.
5. Lee W.R., McQuellon R.P., Case L.D., et al. Early quality of life assessment in men treated with permanent source interstitial brachytherapy for clinically localized prostate cancer. J Urol. 162:1999;403-406.
6. Merrick G.S., Butler W.M., Wallner K.E., et al. Long-term urinary quality of life following permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 56:2003;454-461.
7. Crook J., McLean M., Catton C., et al. Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation. Int J Radiat Oncol Biol Phys. 52:2002;453-460.
8. Terk M.D., Stock R.G., Stone N.N. Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. J Urol. 160:1998;1379-1382.
9. 125I prostate brachytherapy. Brachytherapy. 1:2002;131-137.
10. Tomlinson S.K., Lee W.R., McCullough D.L., et al. Neoadjuvant androgen deprivation increases the risk of acute urinary retention following low dose rate prostate brachytherapy. Int J Radiat Oncol Biol Phys. 54:(Suppl.):2002;273.
11. Kang S.K., Chou R.H., Dodge R.K., et al. Acute urinary toxicity following transperineal prostate brachytherapy using a modified Quimby loading method. Int J Radiat Oncol Biol Phys. 50:2001;937-945.
12. Locke J., Ellis W., Wallner K., et al. Risk factors for acute urinary retention requiring temporary intermittent catheterization after prostate brachytherapy: A prospective study. Int J Radiat Oncol Biol Phys. 52:2002;712-719.
13. Keole S., Ben-Josef E., Cher M., et al. Factors predicting acute urinary retention in patients undergoing prostate brachytherapy. Int J Radiat Oncol Biol Phys. 54:(Suppl.):2002;258-259.
14. Merrick G.S., Butler W.M., Tollenaar B.G., et al. The dosimetry of prostate brachytherapy-induced urethral strictures. Int J Radiat Oncol Biol Phys. 52:2002;461-468.
15. Lee L., Stock R.G., Stone N.N. Role of hormonal therapy in the management of intermediate- to-high risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys. 52:2002;444-452.
16. Merrick G.S., Butler W.M., Galbreath R.W., et al. Does hormonal manipulation in conjunction with permanent interstitial brachytherapy with or without supplemental external beam improve biochemical outcome for intermediate or high risk prostate cancer? British J Urol. 91:2003;23-29.
17. Merrick G.S., Butler W.M., Farthing W.H., et al. The impact of Gleason score accuracy as a criterion for prostate brachytherapy patient selection. J Brachytherapy Int. 14:1998;112-121.
18. Merrick G.S., Butler W.M. Modified uniform seed loading for prostate brachytherapy: Rationale, design and evaluation. Tech Urol. 6:2000;78-84.
19. Merrick G.S., Butler W.M., Dorsey A.T., et al. The effect of prostate size and isotope selection on dosimetric quality following permanent seed implantation. Tech Urol. 7:2001;233-240.
20. Nath R., Anderson L.L., Luxton G., et al. Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. Med Phys. 22:1995;209-234.
21. Butler W.M., Merrick G.S., Dorsey A.T., et al. Comparison of dose length, area, and volume histograms as quantifiers of urethral dose in prostate brachytherapy. Int J Radiat Oncol Biol Phys. 48:2000;1575-1582.
22. Potters L., Torre T., Ashley R., et al. Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy. J Clin Oncol. 18:2000;1187-1192.
23. Merrick G.S., Butler W.M., Wallner K.E., et al. Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy. Urology. 60:2002;650-655.
24. 125I interstitial implantation of the prostate gland. Rad Oncol Invest. 6:1998;135-141.